Equities research analysts expect Synlogic Inc (NASDAQ:SYBX) to announce sales of $200,000.00 for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Synlogic’s earnings. The lowest sales estimate is $100,000.00 and the highest is $300,000.00. Synlogic reported sales of $110,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 81.8%. The company is expected to announce its next quarterly earnings report on Tuesday, March 19th.

On average, analysts expect that Synlogic will report full-year sales of $2.33 million for the current fiscal year, with estimates ranging from $1.31 million to $2.70 million. For the next fiscal year, analysts expect that the business will report sales of $1.01 million, with estimates ranging from $400,000.00 to $2.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Synlogic.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.21. The company had revenue of $1.80 million during the quarter, compared to the consensus estimate of $0.20 million. Synlogic had a negative net margin of 1,912.74% and a negative return on equity of 39.07%.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Synlogic from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research report on Saturday. Wedbush reissued an “outperform” rating on shares of Synlogic in a research report on Friday, September 7th. Oppenheimer set a $18.00 price target on shares of Synlogic and gave the company a “buy” rating in a research report on Monday, November 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Synlogic in a research report on Tuesday, November 13th. Finally, Citigroup lifted their price target on shares of Synlogic to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $18.11.

In related news, insider Paul Francis Miller sold 3,000 shares of Synlogic stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $12.55, for a total value of $37,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 12,000 shares of company stock valued at $135,390. 23.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp acquired a new stake in Synlogic in the 1st quarter worth $249,000. Dimensional Fund Advisors LP acquired a new stake in shares of Synlogic during the 1st quarter valued at about $538,000. Wells Fargo & Company MN acquired a new stake in shares of Synlogic during the 3rd quarter valued at about $351,000. JPMorgan Chase & Co. acquired a new stake in shares of Synlogic during the 3rd quarter valued at about $3,504,000. Finally, Rhumbline Advisers acquired a new stake in shares of Synlogic during the 3rd quarter valued at about $212,000. 80.90% of the stock is owned by institutional investors and hedge funds.

Shares of SYBX stock traded down $0.03 during trading hours on Thursday, hitting $8.74. 88,200 shares of the company were exchanged, compared to its average volume of 134,713. The company has a market cap of $243.28 million, a price-to-earnings ratio of -1.49 and a beta of 2.62. Synlogic has a fifty-two week low of $7.20 and a fifty-two week high of $15.00.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Featured Story: What is the 52-week high/low?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.